Skip to content

Company
Pipeline
For Investors
Contact

Company
Pipeline
For Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 269 Results

July 20, 2021

Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC

June 15, 2021

Relmada Therapeutics to Present Data at the College on Problems of Drug Dependence 83rd Annual Scientific Meeting

June 7, 2021

Relmada Therapeutics Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference

June 1, 2021

Relmada Therapeutics Announces Participation in Jefferies Virtual Healthcare Conference

May 26, 2021

Relmada Therapeutics Announces Oral Poster Presentation on REL-1017 at 2021 American Society of Clinical Psychopharmacology Annual Meeting

May 12, 2021

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results

May 6, 2021

Relmada Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 12, 2021

May 1, 2021

Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021

April 29, 2021

Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting

April 28, 2021

Relmada Therapeutics Announces Participation in the 7th Annual Truist Securities Life Sciences Summit

«...10 111213 14 15...»

IR Contact

Brian Ritchie
LifeSci Advisors, LLC

+1 (212) 915-2578
britchie@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Company

Pipeline
Overview
NDV-01
Speranolone

For Investors
Summary
News
Events
SEC Filings
Corporate Governance
Stock Information

Contact

info@relmada.com

+1 (786) 629-1376

©2026 Relmada Therapeutics, Inc.

Privacy Policy
Terms of Use

Scroll to Top